Genentech has joined the SNM Clinical Trials Network, an initiative designed to address the need for streamlined drug discovery through the integration of imaging biomarkers into multi-center clinical trials.
SNM inaugurated the Clinical Trials Network in late 2008 to facilitate more cost-effective drug development through the integration and standardization of imaging biomarkers into Phase 1, 2, 3 and 4 therapeutic clinical trials.
Peter S. Conti, MD, PhD, co-chair of the SNM Clinical Trials Network said that the use of imaging in clinical trials can help pharmaceutical developers determine earlier in the development process whether a new product is clinically promising by allowing physicians to see and assess whether it is working as intended for a patient.
"Molecular imaging is an essential component of such studies since it accelerates the development of promising compounds and eliminates those without apparent patient benefit earlier in the development cycle," he added. "We hope that Genentech's collaboration with SNM will help improve patient treatment worldwide."
For more information about the SNM Clinical Trials Network, please visit www.snm.org/clinicaltrials.